Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
10.3971/j.issn.1000-8578.2023.22.1423
- VernacularTitle:后PD-1/PD-L1抑制剂时代肿瘤治疗展望
- Author:
Baoen SHAN
1
Author Information
1. Scientific Research Center of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
- Publication Type:Research Article
- Keywords:
Tumor immunotherapy;
Immune checkpoint inhibitors therapy;
PD-1/PD-L1 antibody
- From:
Cancer Research on Prevention and Treatment
2023;50(9):833-841
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors restart and maintain cancer-immunity circulation to normalize the anti-tumor immunity. Currently, anti-PD-1/PD-L1 antibodies, as new milestone in immunotherapy, have significantly improved the prognosis of patients with various malignant tumors. However, anti-PD-1/PD-L1 antibody alone exhibited a low response rate, and the combination of anti-PD-1/PD-L1 antibody with traditional therapies such as surgery, chemotherapy, radiotherapy and targeted therapy have shown great potential. As new immune checkpoint inhibitors or in combination therapy are on the way, tumor immunotherapy is entering the era of post-anti-PD-1/PD-L1 antibody. The methodology of combination therapy and biomarker screening remain the focus. This paper reviews the current status of immune checkpoint inhibitor therapy and makes a perspective for the future of post-anti-PD-1/PD-L1 antibody era.
